What is the recommended treatment for Mycoplasma genitalium infections?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 23, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment for Mycoplasma genitalium Infections

For confirmed M. genitalium infections, use azithromycin 500 mg orally on day 1, followed by 250 mg daily for days 2-5 (extended regimen), which achieves 93-99% cure rates while minimizing macrolide resistance development. 1

Diagnostic Testing Before Treatment

  • Confirm M. genitalium infection using nucleic acid amplification testing (NAAT) before initiating therapy, rather than treating empirically 1
  • Test simultaneously for gonorrhea and chlamydia, as co-infections are common and require different treatment approaches 1, 2
  • If available, perform macrolide resistance testing to guide therapy selection 3

Critical caveat: The 2010 CDC guidelines 4 predate our understanding of macrolide resistance and recommend azithromycin 1 g single dose, but this approach is now outdated and should be avoided.

First-Line Treatment Algorithm

For macrolide-susceptible or unknown resistance status:

  • Azithromycin 500 mg orally on day 1, then 250 mg orally daily for days 2-5 1, 3
  • This extended regimen achieves 95-99% cure rates 1 and causes resistance in only 2.6% of cases 5

Why the extended regimen is superior:

  • Azithromycin 1 g single dose has a 13.9% treatment failure rate and causes macrolide resistance in 12% of patients 6
  • The extended 5-day regimen reduces treatment failure to 3.7% 6
  • Single-dose azithromycin selected for resistance in 100% of treatment failures in one Swedish study 7

Second-Line Treatment for Macrolide-Resistant Infections

For confirmed macrolide resistance or treatment failure:

  • Moxifloxacin 400 mg orally once daily for 7-10 days 3
  • Cure rate is 92.2% for macrolide-resistant infections 5
  • However, moxifloxacin efficacy has declined from 100% pre-2010 to 89% post-2010 due to emerging fluoroquinolone resistance 8

Role of Doxycycline

  • Doxycycline 100 mg orally twice daily for 7 days has only 30-40% cure rate as monotherapy 2, 3
  • However, doxycycline as initial therapy before azithromycin reduces bacterial load by 2.60 log10 and improves subsequent cure rates to >92% 5
  • Doxycycline does not induce resistance, making it useful as a "priming" agent 3

Patient Instructions and Partner Management

  • Abstain from sexual intercourse for 7 days after completing single-dose therapy or until completion of multi-day regimens 1, 2
  • All sexual partners require evaluation and treatment, even if asymptomatic, to prevent reinfection 1
  • Dispense medications on-site when possible and directly observe the first dose to maximize compliance 1

Follow-Up Requirements

  • Patients should return if symptoms persist or recur after treatment, indicating treatment failure requiring resistance testing 1
  • Test of cure should be performed 14-90 days after treatment completion 5
  • Avoid testing before 3 weeks post-treatment, as NAAT may detect non-viable organisms and yield false-positive results 1
  • Repeat testing at 3-6 months is recommended due to high reinfection rates 1
  • Test for other STIs including syphilis and HIV 9

Complicated Infections

For pelvic inflammatory disease or epididymitis caused by M. genitalium:

  • Moxifloxacin 400 mg orally once daily for 14 days 3

References

Guideline

Treatment for Mycoplasma genitalium

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Treatment for Mycoplasma Genitalium

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

2016 European guideline on Mycoplasma genitalium infections.

Journal of the European Academy of Dermatology and Venereology : JEADV, 2016

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Outcomes of Resistance-guided Sequential Treatment of Mycoplasma genitalium Infections: A Prospective Evaluation.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2019

Guideline

Treatment of Mycoplasma Infections in Men

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.